Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)
Summary of the evidence on eravacycline for complicated intra-abdominal infections in adults
Search results
171 results
-
-
Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)
Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults
-
Melatonin for treating sleep disorders in adults who are blind (ES38)
Summary of the evidence on melatonin for treating sleep disorders in adults who are blind
-
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults
-
Antimicrobial prescribing: nebulised liposomal amikacin (ES36)
Summary of the evidence on nebulised liposomal amikacin for non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex in adults
-
Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
-
COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
-
COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
-
Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)
Summary of the evidence on antimicrobial prescribing: delafloxacin
-
Antimicrobial prescribing: cefiderocol (ES31)
Summary of the evidence on antimicrobial prescribing: cefiderocol
-
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
-
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
-
COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)
This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).
-
COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
-
COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis (ES26)
ES26 . Key messages The content of this evidence review was up to date on 13 May 2020. New evidence may have been published since
-
COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 (ES24)
ES24 . Key messages The content of this evidence review was up to date on 1 April 2020. New evidence may have been published since
-
COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES25)
ES25 . Key messages The content of this evidence review was up to date on 20 April 2020. New evidence may have been published since
-
COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)
ES23 . Key messages The content of this evidence review was up to date on 24 March 2020. New evidence may have been published since
-
Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
-
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
-
Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)
Summary of the evidence on doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy in women aged 18 years and older to inform local NHS
-
Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (ES19)
Summary of the evidence on buprenorphine prolonged-release subcutaneous injection (Buvidal) for opioid dependence to inform local NHS
-
Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)
This evidence summary has been updated and replaced by NICE guideline 115.
-
Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)
This evidence summary has been updated and replaced by NICE guideline 115.
-
Antimicrobial prescribing: Ceftazidime/avibactam (ES16)
Summary of the evidence on ceftazidime/avibactam for complicated intra-abdominal and UTI infections and hospital-acquired pneumonia
-
Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)
Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer
-
Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)
This evidence summary has been updated and replaced by NICE technology appraisal guidance 664.
-
Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)
This advice has been updated and replaced by NICE guideline NG199.
-
Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)
ES12 Key points The content of this evidence summary
-
Mitochondrial disorders in children: Co-enzyme Q10 (ES11)
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
-
Hyperhidrosis: oxybutynin (ES10)
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
-
Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)
Summary of the evidence on opicapone for reducing end-of-dose motor fluctuations in Parkinson’s disease to inform local NHS planning and decision-making
-
Narcolepsy with or without cataplexy in adults: pitolisant (ES8)
Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making
-
Skin involvement in systemic sclerosis: rituximab (ES7)
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
-
Parkinson's disease with motor fluctuations: safinamide (ES6)
Summary of the evidence on safinamide for treating Parkinson’s disease with motor fluctuations to inform local NHS planning and decision-making
-
Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)
Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders
-
Refractory extrapulmonary sarcoidosis: infliximab (ES4)
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
-
Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate (ES3)
Summary of the evidence on conjugated oestrogens and bazedoxifene acetate for oestrogen deficiency symptoms to inform local NHS planning and decision-making
-
Pulmonary sarcoidosis: infliximab (ES2)
Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making
-
Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)
Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making
-
Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)
Summary of the evidence on Truvada (emtricitabine/tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) of HIV in adults at high risk
-
Moderate to severe acute post-operative pain: fentanyl transdermal system (ESNM77)
This evidence summary was withdrawn in September 2017 as the medicine is no longer available.
-
Visual impairment due to myopic choroidal neovascularisation: aflibercept (ESNM76)
This evidence summary has been replaced by NICE technology appraisal guidance 486.
-
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
-
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making
-
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
-
Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)
This evidence summary has been updated and replaced by NICE guideline 115.
-
Moderate to severe acute post-operative pain: sufentanil sublingual tablet system (ESNM71)
Summary of the evidence on the sufentanil sublingual tablet system for treating postoperative pain to inform local NHS planning and decision-making
-
Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)
Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making
-
Pulmonary hypertension in neonates: sildenafil (ESUOM51)
Summary of the evidence on sildenafil for treating pulmonary hypertension in neonates to inform local NHS planning and decision-making